SEC Tracker
Get the app

vTv Therapeutics VTVT

vTv Therapeutics Q1 FY24: revenue $1.0M

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers vTv Therapeutics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$4.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$52.3MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$7.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when vTv Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ovid Therapeutics OVID public float $22M, Jun 30, 2025
  2. Marimed MRMD public float $23M, Jun 30, 2025
  3. Aptose Biosciences APTOF public float $22M, Jun 28, 2025
  4. Dare Bioscience DARE public float $21M, Jun 30, 2025
  5. Lunai Bioworks LNAI public float $21M, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.